The pharmaceutical composition of the present invention provides a covalent closure having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA, including any disease associated with hepatitis B infection and the formation of covalently closed circular DNA. Contains a circular DNA formation inhibitor.本発明の薬学的組成物は、B型肝炎感染および共有結合閉環状DNAの形成を伴う任意の疾患を含む共有結合閉環状DNAの形成に関連する疾患の治療において疾患修飾作用を有する共有結合閉環状DNA形成阻害剤を含む。